William John Sibold - Sep 11, 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
President and CEO, Director
Signature
/s/ Brian J. Lynch
Stock symbol
MDGL
Transactions as of
Sep 11, 2023
Transactions value $
$0
Form type
4
Date filed
9/13/2023, 04:41 PM
Previous filing
Sep 13, 2023
Next filing
Jan 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Award $0 +50K $0.00 50K Sep 11, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Performance Restricted Stock Units Award $0 +50K $0.00 50K Sep 11, 2023 Common Stock 50K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units, which vest as to 25% of the shares on each of September 8, 2024, September 8, 2025, September 8, 2026 and September 8, 2027, provided the Reporting Person continues in service with the Issuer on each such date.
F2 Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level.

Remarks:

** As attorney-in-fact for Reporting Person